<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436890</url>
  </required_header>
  <id_info>
    <org_study_id>GRC 4039-204</org_study_id>
    <secondary_id>2011-000270-57</secondary_id>
    <nct_id>NCT01436890</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Study the Effects of Revamilast in Patients With Chronic Persistent Asthma</brief_title>
  <official_title>A Phase II, 12-week Randomized, Double-blind, Triple Dummy, Parallel Group, Placebo-controlled, Dose Range Finding Study to Evaluate Safety, Tolerability and Efficacy of Revamilast in Patients With Chronic Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Pharmaceuticals Ltd. India</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glenmark Pharmaceuticals S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Glenmark Pharmaceuticals Ltd. India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthma is a common, chronic inflammatory disease of the bronchial airways, with a reported
      prevalence in most industrialized countries of between 5 to 10 % of the adult population.
      Asthma is clinically characterized by repeated episodes of wheezing, breathlessness, chest
      tightness, and coughing; usually in the presence of variable airflow obstruction that is
      often reversible either spontaneously or with treatment (The Global Initiative for Asthma
      (GINA), 2009).

      Drug treatment of asthma has focused on anti-inflammatory therapy in all but the mildest,
      intermittent cases. Inhaled corticosteroids have been shown to be anti-inflammatory in
      asthma, but chronic use of these agents may be associated with a range of side effects,
      especially at high doses. In asthma, there remains a need for the development of novel
      anti-inflammatory therapies that are at least equally effective and possess a superior safety
      profile in comparison to corticosteroids.

      This is a randomized, double-blind, triple dummy, placebo controlled, parallel group, dose
      ranging study. The study will be conducted in adult patients with a diagnosis of chronic
      persistent asthma with an Forced Expiratory Volume in one second(FEV1) of 50% to 80% of the
      predicted value. Study will enroll 448 patients globally (278 from India) across different
      centers.

      Patients will be recruited after providing written informed consent. After screening and run
      in period, patient will be randomized (patient meeting randomization criteria) in 1:1:1:1
      ratio to receive either one of the three dose regimens of revamilast or placebo.

      The primary objective of the study is to evaluate the effect of revamilast on lung function
      as assessed by Forced Expiratory Volume in one second (FEV1) after the therapy (12 weeks).
      Secondary objective includes area under curve for FEV1, Change in asthma symptoms, patient /
      investigator's global assessments and safety. Patients will be followed for safety and
      efficacy assessment at week 1, 4, 8 12 and 14 after start of therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Forced Expiratory Volume in One Second (FEV1) from baseline to week 12</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in morning pre-dose Forced Vital Capacity (FVC) from baseline to week 12</measure>
    <time_frame>baseline to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in asthma day time symptom score from baseline to week 12</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of asthma exacerbations during treatment period</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in investigator global impression from baseline to week 12</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>An investigator-rated test measured on a 7-point scale, used to rate change in a patient's condition over the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient global impression from baseline to week 12</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>A patient-rated test measured on a 7-point scale, used to rate change in a patient's condition over the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in morning pre-dose Peak Expiratory Flow (PEF) from baseline to week 12</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in morning pre-dose PEF25-75% (Forced expiratory flow 25-75%) from baseline to week 12</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">273</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose revamilast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose Revamilast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose Revamilast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo in triple dummy format</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revamilast</intervention_name>
    <description>Tablet. Low dose, Once daily for 12 weeks</description>
    <arm_group_label>Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revamilast</intervention_name>
    <description>Medium dose, Once daily for 12 weeks</description>
    <arm_group_label>Medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revamilast</intervention_name>
    <description>High dose, Once daily for 12 weeks</description>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet in triple dummy format, Once daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient provides written informed consent to participate in the study

          2. Male or female patient aged 18 to 65 years

          3. Documented diagnosis of asthma

          4. Forced Expiratory Volume in One Second (FEV1) between 50% and 80% of the predicted
             value

          5. Patient judged by the investigator to be in otherwise good stable health based on
             medical history, physical examination, and routine laboratory data

          6. Female participants must have a negative pregnancy test at screening visit

          7. Males must agree to use barrier contraception while on study medication and for 90
             days after taking the last dose of study medication

        Exclusion Criteria:

          1. Pregnant or lactating women

          2. Female subjects on hormone replacement therapy or hormonal contraceptives

          3. Suffering from relevant lung diseases (other than asthma) causing impairment in lung
             function

          4. Past smoker with a history of ≥10 pack per year or current smoker

          5. Recent change in the patient's usual asthma treatment

          6. Patients with risk factors for asthma exacerbation during the study, including (any of
             the following):

               -  Current requirement for &gt; 8 puffs per day of reliever medication.

               -  Hospitalization for asthma

               -  Treatment with systemic corticosteroid therapy within 3 months

          7. Evidence of current or recent neoplastic disease

          8. Clinically significant cardiovascular, haematological, endocrine, neurological,
             gastrointestinal, psychiatric, metabolic, immunologic, infectious, hepatic, renal,
             gynaecological disease or other condition that the investigator considers detrimental
             to the patient's participation in the study or that may prevent the successful
             completion of the study

          9. Positive serology for an infectious disease (including hepatitis B or C) at screening
             and known case of human immunodeficiency virus [HIV]

         10. Patients who have been hospitalized for any psychiatric illness in the past year, or
             are diagnosed with major depression

         11. Clinically significant ECG Abnormality at baseline

         12. Patients with documented or suspected or current history of alcohol and drug abuse

         13. Patients who have undergone lung surgery in the previous year

         14. Participation in an investigational drug trial during 30 days preceding screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Ballari Brahmachari</last_name>
    <role>Study Director</role>
    <affiliation>Glenmark Pharmaceuticals Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HORNMED s.r.o.</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sdružená pneumologická a anesteziologická ambulance</name>
      <address>
        <city>Jindřichův Hradec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private pulmonatory ambulance</name>
      <address>
        <city>Neratovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kunal Institute of Medical Specialities Pvt. Ltd</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narayana Medical College &amp; Hospital</name>
      <address>
        <city>Nellore</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yashoda Hospital</name>
      <address>
        <city>Secunderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vasavi Hospital and Research Centre</name>
      <address>
        <city>Hyderabad</city>
        <state>Andra Pradesh</state>
        <zip>500009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saboo hospital and research centre</name>
      <address>
        <city>Hyderabad</city>
        <state>Andra Pradesh</state>
        <zip>500012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutuja Allergy , Chest and General Clinic</name>
      <address>
        <city>Ponda</city>
        <state>Goa</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gujarat Pulmonary &amp; Critical Care Clinic</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chest and Maternity Centre</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M S Ramaiah Medical College &amp; Teaching Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narayanan Hrudayalaya Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasturba Medical College Hospital</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westfort Hi-tech Hospital Ltd</name>
      <address>
        <city>Thrissur</city>
        <state>Kerala</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indore Chest Centre</name>
      <address>
        <city>Indore</city>
        <state>Madhya Pradesh</state>
        <zip>452001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Aly Khan Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Bhatia Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KRIMS Hospitals</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Getwell Hospital &amp; Research Institute</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chest Research Foundation</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shwaas Center, Navkar Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajastan</state>
        <zip>302023</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma Bhawan</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Khippal's Clinic</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chennai Thoracic Research Institute</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Allergy Asthma Bronchitis Institute</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T B and Chest Disease Hospital</name>
      <address>
        <city>Goa</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAMC &amp; Associated Lok Nayak Hospitals</name>
      <address>
        <city>New Delhi</city>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ 'Promedica'</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nzoz Clinica Vitae</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landa Specjalistyczne Gabinety Lekarskie</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatna Praktyka Lekarska</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatny Gabinet Specjalistyczny</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cdt Medicus</name>
      <address>
        <city>Lubin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Alergologii Teresa Hofman</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Lucyna Andrzej Dymek</name>
      <address>
        <city>Strzelce Opolskie</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution</name>
      <address>
        <city>Elektrostal</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of Russian Academy of Science</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution of Moscow</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Healthcare Institution</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Chest Hospital Department of Respiratory Medicine</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>India</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2011</study_first_submitted>
  <study_first_submitted_qc>September 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2011</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Persistent Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

